MCRB News and Press, Seres Therapeutics Inc. From 05/30/23

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores,...

2023-05-23 14:14:06 ET Summary Good preliminary results with a second generation product in blood bacterial infections. The Ulcerative Colitis program is still alive. Excessive cash burn in Q1 2023 explained in part by the manufacture of VOWST. Review of cost savings across th...

2023-05-22 14:49:12 ET Summary SER-109 (Vowst) was recently approved by FDA and will be launched in June with the Nestle commercial team. Most of the pipeline has failed in clinical trials. There is one active, albeit early stage clinical program, SER -155. The company bur...

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...

2023-05-09 13:48:14 ET Start Time: 08:30 End Time: 09:18 Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Eric Shaff - President and CEO Terri Young - EVP, Chief Commercial and Strategy Officer ...

2023-05-09 07:04:12 ET Seres Therapeutics press release ( NASDAQ: MCRB ): Q1 GAAP EPS of -$0.57 misses by $0.02 . Seres ended the first quarter of 2023 with $106.5 million in cash, cash equivalents and investments as compared with $181.3 million at the end of 2022. ...

– VOWST ™ microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; product availability expected in June – – New SER-155 Phase 1b Cohort 1 clinical data show ...

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen domination provides support for intended SER-155 clinical activity – ...

2023-05-08 14:34:13 ET Seres Therapeutics ( NASDAQ: MCRB ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate is $1.58M (+6.0% Y/Y). Over the last 3 months, EPS e...

– Data from Phase 3 open-label single-arm study of VOWST found nearly 95% of individuals with a clinical response at 8 weeks remained free of CDI through Week 24, regardless of number of prior C. difficile infections (CDI) – – Results from ECOSPOR IV ...